Two-vote system year | these pharmaceutical companies recorded good growth

Pharmaceutical Network December 25 hearing 2017 is about to end, the national two-vote policy is also about the first anniversary of the year - this year, some decline in performance of pharmaceutical companies 'pot' made two votes 'back', looks like two Ticket system is a scourge of floods; however, more pharmaceutical companies have achieved good growth in the background of two-vote system, of which the leading drug makers in the region are the most dazzling ......

According to the data released by the Ministry of Industry and Information Technology (MIIT) recently released in the first half of this year, the total operating profit of the pharmaceutical industry for the first half of 2017 was RMB255.726 billion, up 17.54% over the same period of previous year, up from 15.64% in the same period of last year, An increase of 1.9 percentage points over the same period of 2009. It is estimated that the total profit of the pharmaceutical industry for the year will be substantially increased compared with last year.

Visible, experienced a two-vote system, the proportion of medicine, health care control fees and other management pains, the third quarter also changed the first half net profit growth down year on year trend.

Among the various sub-sectors, the fastest-growing sectors are biological products manufacturing and chemistry drug Preparations, pharmaceutical equipment from the negative growth in the first half to the current basically the same level in the first half of 2017 medicine Industrial main revenue margin of 9.84%.

The distribution of profits of each sub-sector from January to September 2017 is as follows:

(Note: the data from the Ministry of Industry and Information, for reference)

Most pharmaceutical companies pre-performance, many pharmaceutical companies in the fourth quarter results to catch up

A few days left in a year, the operation of the year has basically been established.As time goes by, more and more pharmaceutical companies released a full-year performance notice.

According to the author's statistics, up to now nearly 80 pharmaceutical companies have released the annual results notice, accounting for the entire pharmaceutical industry, 30% of listed companies, 'glimpse' of the three percent of the company's annual results this 'spot' can be the first foreseen the entire pharmaceutical General overview of the industry throughout the year.

According to the statistics, the overall situation is more optimistic than the performance forecast of the third quarter.

Most of the companies are pre-increased and pre-paid, of which 54 were net profit-increase over the same period of the previous year, 2 were net profit-earning companies, 8 were net profit and 7 were net loss pre-deductions , 3 (Note: At the time of the third quarter of more than 80 performance notice, the total pre-losing, pre-reduction of nearly 20), in addition to seven currently not yet confirmed. Thus, there are many business performance in Catch up in the fourth quarter!

From the breakdown of categories, the five pharmaceutical commercial companies that have disclosed their annual results notice are all pre-increased. The two-vote policy in various places has been continuously implemented, forming a positive result for big drug dealers and local leading drug dealers. As a result, their performance also contributed to the performance of their businesses growth of.

More than 82% of pre-registered enterprises have released pre-sales performance forecasts. This is a category with a high pre-growth share. This may be related to the country's increasing support for traditional Chinese medicine policy in recent years, Medicinal herbs Strengthen the control, the development of proprietary Chinese medicine industry gradually standardized, and the corresponding auxiliary medication, focus on monitoring the variety of contents of the proprietary Chinese medicine industry impact or not big enough.

The pre-loss, pre-reduction of the relatively high proportion of categories are health care and chemical medicine.Health care or medical institutions in these two years to strengthen monitoring and increase the intensity of medical anti-corruption; and chemical or pharmaceutical industry or generic and drug evaluation The strong advancement, limited resistance and large transfusion policy regulatory overweight, monitoring and other multi-pronged management of drug control measures.

(Note: the data according to the Eastern Wealth Network data sorting, industry segments according to Mastery, for reference)

According to the five pharmaceutical commercial companies that have released their performance forecasts, they all performed well.

Among them, the best-performing Ruikang Pharmaceuticals is expected to have a 40% increase in full-year results and be optimistic to nearly double the growth.

This has been a substantial expansion after the listing of enterprises, and constantly in the staking market to buy and buy related businesses have moved from Shandong to the country in the past two years, the country more than 180 pharmaceutical, equipment, testing and other commercial companies Nari Under his command, complete the country's more than 30 provincial-level administrative area of ​​the full coverage.

In addition, the four companies that disclosed the results, namely Yixintang, Jiatang, Luyan and Huatong, were the leading distributors or retailers of regional distributors with positive growth in performance.

It can be seen that the "two-vote system" is not a scourge, but only bells and whistles for those unmanaged and unequivocal over-the-counter companies, and for some regional leading enterprises, enterprises that are good at capital operation and mergers and acquisitions have brought about great development Timing, some companies are likely to achieve this corner overtaking.

The specific performance of the five commercial enterprises in the following table:

(Note: the data comes from the East Wealth Network, subdivision industry classification according to Mastery, the data for reference)

Among the nearly 80 pharmaceutical companies that have released their performance forecasts, 56 of them have seen their net profit increased over the same period of the previous year, of which 51 were industrial enterprises.

Among them, it is clear that more than double the growth of enterprises have health yuan, Livzon Group, Shuangcheng Pharmaceutical, Berry Gene, etc .; In addition, Lai Mei Pharmaceutical, human welfare medicine, Year-on-year growth, but clearly a substantial year-on-year growth.

Among them, the first three quarters of the human well-being of the pharmaceutical industry increased 2.11 times the net profit growth is expected to 2 times the annual results, widely known far and the semi-annual report an increase of 1.16 times, is expected to increase year on year about 1 times; The net profit of the first three quarters of the industry increased by only 60% over the same period of last year, and it is estimated that more than 50% of the net profit will be realized throughout the year.

Among them, Berry Gene due to a low net profit base in 2016 this year a substantial increase of 50-60 times; Livzon Group and Health yuan are due to the sale of real estate to obtain higher one-time gains, to achieve 3-5 times the growth, Before the ring is heat transfer 'Livzon sold a piece of land, top income Heng Ding Rui 2-year net profit'.

The changes in the specific performance of 51 pharmaceutical industrial enterprises with net profit growth are as follows:

(Note: the data comes from the East Wealth Network, subdivision industry classification according to Mastery, the data for reference)

Of the 80 pharmaceutical companies that already issued their performance forecasts, 8 of them dropped their net profit or lost profits. As predicted by the performance figures of the same number of enterprises in the first three quarters, the share of such enterprises dropped by nearly 50%; there were 7 results Still not clear is the growth or decline, while another 8 companies are expected to be the same as last year's performance.

The author also found a hidden worries through the data found that some individual companies listed in 2016-2017, such as Yi-ming Pharmaceutical, Sialon Pharmaceutical results are not satisfactory, Yi Ming Pharmaceutical net profit decline, Sialon Pharmaceutical growth less than 10 A percentage point.

On the one hand it is estimated that the performance of overdrafts for the listing, on the other hand these companies are not strong powerful pharmaceutical companies, the regulatory policies for the pharmaceutical industry and the changes in the environment response measures are limited.

Still other pharmaceutical companies saw substantial growth in operating income and sharp drop in net profit, such as Longjin Pharmaceutical and Ji'an Medical, or they sacrificed short-term profits for long-term development.

Longjin Pharmaceutical is expected to decline mainly due to changes in sales mode.

According to its three quarterly show, its operating income increased by more than 40%, net profit but dropped nearly 60%, because the company changed the marketing model, to promote sophisticated marketing strategy, directly responsible for or jointly build the original proxy As a result, sales expenses increased nearly threefold. Therefore, the net profit for the full year is expected to decline 15% -65%.

Its third quarterly report shows operating income growth of nearly 40%, mainly due to mergers and acquisitions overseas market performance and consolidated financial statements, but its current liabilities due within one year more than 294 million yuan, an increase of 300 times! In addition, due to exchange rate and other factors Financial consolidated income nearly 30 million loss, it is even more enterprise Short-term performance worse.

The following table shows the changes in the specific performance of 23 industrial enterprises whose net profit declines, is flat and is uncertain or is an increase or decrease: